Irish Medicines Board

The Irish Medicines Board carries out the following services within Ireland:

  • Licensing of medicinal products for human use
  • Licensing of veterinary products
  • Licensing of wholesalers and manufacturers of human and veterinary medicines
  • Pharmacovigilance & Drugs safety monitoring
  • Clinical Trial Licensing
  • Inspection of wholesale and manufacturing sites
  • contact
    Earlsfort Centre, Earlsfort Terrace, Dublin 2
    Telephone:+353 1 6764971
    Fax:+353 1 676 7836

    Main Contacts
    Dr. Vincent Irwin

    The Role of the Irish Medicines Board
    The objective of the Irish Medicines Board is to ensure in so far as possible, consistent with current medical and scientific knowledge, the quality, safety and efficacy of medicines available in Ireland and to participate in systems designed to do that throughout the European Union.

    Before a medicinal product can be authorised for use, an application must be made to the Irish Medicines Board and this must contain all of the necessary data supporting its quality, safety and efficacy. Members of staff of the IMB together with the assistance of the Board's committees and individual experts review the scientific aspects of the application and reach a conclusion on the likely balance of any benefits versus risk of the product before arriving at a decision. Following approval and use of a medicine, the IMB monitors the type and frequency of any reported side-effects.

    It is vital that healthcare professionals report suspected adverse effects and quality defects, since this forms an important part of the Irish Medicines Board's role. In addition, there is a responsibility on the holders of product authorisations to keep the IMB informed of events with potential safety consequences for their products.

    The Irish Medicines Board also monitors the quality of medicines by conducting inspections at sites of manufacture and distribution of medicines and by random sampling of products both pre and post authorisation. The use of medicines for clinical research purposes also falls within the IMB's remit.

    In the case of veterinary medicines there must likewise be assurance of quality, safety and efficacy but in addition the consequences to human health of the use of medicines in animals must be considered.

    The Chief Executive is responsible for the day to day activities of the Irish Medicines Board with the assistance of an Executive Committee composed of the heads of the various departments, namely Medical, Veterinary, Pharmacy, Inspections and Finance & Administration.